Abstract

Electrospray ionization mass spectrometry (ESI MS) is a powerful investigative tool to analyze the reactions of metallodrugs with proteins and peptides and characterize the resulting adducts. Here, we have applied this type of approach to four experimental anticancer gold(III) compounds for which extensive biological and mechanistic data had previously been gathered, namely, Auoxo6, Au2phen, AuL12, and Aubipyc. These gold(III) compounds were reacted with two representative proteins, i.e., human serum albumin (HSA) and human carbonic anhydrase I (hCA I), and with the C-terminal dodecapeptide of thioredoxin reductase. ESI MS analysis allowed us to elucidate the nature of the resulting metal–protein adducts from which the main features of the occurring metallodrug–protein reactions can be inferred. In selected cases, MS data were integrated and supported by independent 1HNMR and UV–Vis absorption measurements to gain an overall description of the occurring processes. From data analysis, it emerges that most of the investigated gold(III) complexes, endowed with an appreciable oxidizing character, undergo quite facile reduction to gold(I); the resulting gold(I) species tightly associate with the above proteins/peptides with a remarkable selectivity for free cysteine residues. In contrast, in the case of the less-oxidizing Aubipyc complex, the gold(III) oxidation state is conserved, and a gold(III) fragment still containing the original ligand is found to be associated with the target proteins. It is notable that the C-terminal dodecapeptide of thioredoxin reductase containing the characteristic –Gly–Cys–Sec–Gly metal-binding motif is able in all cases to trigger gold(III)-to-gold(I) reduction. Our investigation allowed us to identify in detail the nature of the gold fragments that ultimately bind the protein targets and determine the exact binding stoichiometry; some insight on the reaction kinetics was also gained. Notably, a few clear correlations could be established between the structure of the metal complexes and the nature of the resulting protein adducts. The mechanistic implications of these findings are analyzed and thoroughly discussed. Overall, the present results set the stage to better understand the real target biomolecules of these gold compounds and elucidate at the atomic level their interaction modes with proteins and peptides.

Highlights

  • During the last two decades, a number of studies highlighted the importance of gold compounds as a new family of cytotoxic agents with the potential of becoming new effective anticancer drug candidates endowed with original mechanisms of action and a peculiar spectrum of antitumor activities (Nobili et al, 2010; Zou et al, 2015)

  • In contrast with the results described for the previous gold(III) compounds, in this case, the lack of adducts formed with cysteinylated human serum albumin (HSA) suggests that this modification of the only free cysteine prevents the reaction with Aubipyc

  • More precisely: (i) Upon incubation with HSA, AuL12 shows the same fragmentation pattern seen upon interaction with bovine serum albumin (BSA) (Pratesi et al, 2019). In this case, it is possible to identify two small molecules originated from AuL12 degradation mechanisms, i.e., ethanol (δ 3.64, 1.17) and ethyl sarcosinate (δ 4.30, 3.96, 2.79, 1.29). This occurrence is in agreement with Electrospray ionization mass spectrometry (ESI MS) data, in which only a gold/HSA adduct is visible in the spectrum, with a complete loss of the ligand from the metal center

Read more

Summary

INTRODUCTION

During the last two decades, a number of studies highlighted the importance of gold compounds as a new family of cytotoxic agents with the potential of becoming new effective anticancer drug candidates endowed with original mechanisms of action and a peculiar spectrum of antitumor activities (Nobili et al, 2010; Zou et al, 2015). In this case, it is possible to identify two small molecules originated from AuL12 degradation mechanisms, i.e., ethanol (δ 3.64, 1.17) and ethyl sarcosinate (δ 4.30, 3.96, 2.79, 1.29) (see Supplementary Figure 5) This occurrence is in agreement with ESI MS data, in which only a gold/HSA adduct is visible in the spectrum, with a complete loss of the ligand from the metal center. Regarding Aubipyc, the different biomolecules promote the formation of different binding moieties; in the case of HSA and hCA I, the metal complex retains its oxidation state (+3), and the [Au(III)(bipydmb-H)]2+ fragment binds the proteins, while in the presence of the dodecapeptide, a reduction of the gold center occurs, and the formation of Au(I)–peptide adduct is revealed. The results of our work, highlighting the behavior of the gold(III) complexes in the presence of different biomolecules, seem to be an additional evidence to support the importance of redox mechanisms in the biological activity of these compounds

MATERIALS AND METHODS
DATA AVAILABILITY STATEMENT
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call